Response to imatinib mesylate therapy
. | No. (%) . | . | . | |
|---|---|---|---|---|
| Response . | Study group . | Historical group . | P . | |
| Complete hematologic | 112 (98) | 49 (98) | — | |
| Cytogenetic | 110 (96) | 49 (98) | — | |
| Complete | 103 (90) | 37 (74) | .01 | |
| Partial | 6 (5) | 9 (18) | — | |
| Minor | 1 (1) | 3 (6) | — | |
. | No. (%) . | . | . | |
|---|---|---|---|---|
| Response . | Study group . | Historical group . | P . | |
| Complete hematologic | 112 (98) | 49 (98) | — | |
| Cytogenetic | 110 (96) | 49 (98) | — | |
| Complete | 103 (90) | 37 (74) | .01 | |
| Partial | 6 (5) | 9 (18) | — | |
| Minor | 1 (1) | 3 (6) | — | |
Populations are as follows: study group, N = 114; historical group, N = 50. —indicates lack of statistical significance.